Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated With Rituximab Plus Infusional EPOCH (AMC-034 Trial)

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-0466
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Pooled Analysis of AIDS Malignancy Consortium Trials Evaluating Rituximab Plus CHOP or Infusional EPOCH Chemotherapy in HIV-associated Non-Hodgkin Lymphoma

Cancer
Cancer ResearchOncology
2011English

Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated With Dose-Adjusted EPOCH Plus Rituximab

American Journal of Hematology
Hematology
2017English

Statin Use and Prognosis in 12,865 Non-Hodgkin Lymphoma Patients Treated in the Rituximab-Era

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Rituximab Plus ABVD in Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma

British Journal of Haematology
Hematology
2016English

Prediagnostic Serum Levels of Cytokines and Other Immune Markers and Risk of Non-Hodgkin Lymphoma

Cancer Research
Cancer ResearchOncology
2011English

MicroRNA-related Polymorphisms and Non-Hodgkin Lymphoma Susceptibility in the Multicenter AIDS Cohort Study

Cancer Epidemiology
Cancer ResearchEpidemiologyOncology
2016English

Non-Hodgkin Lymphoma of the Stomach in a Patient Treated With Natalizumab

Clinical Medicine Insights: Oncology
Oncology
2015English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Subcutaneous Rituximab in B-Cell Non-Hodgkin Lymphoma: A Single-Center Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy